Today, I am sharing something a little bit different from that which I typically write.
One of the “elephants under the carpet” in the medical world is the awareness that long-term management of chronic illness is much more profitable than finding cures. And since all apparent trends suggest that, in general, pharmaceutical (and possibly genetic?) companies’ first concern is for their shareholders rather than their customers, it makes sense that the search for/discovery of cures (especially non-patentable natural ones) are frequently hindered at best and covered up at worst. I have witnessed this firsthand for decades in the domains of cancer and diabetes. Now, thanks to a CNBC report, we have a window (and in a sense an acknowledgement) of this dilemma that costs so many people in both the quality and quantity of their lives.
As reported in CNBC, this issue of healing vs profits is clearly revealed in a recent internal Goldman Sachs report in which the company is questioning whether or not curing chronic illness is compatible with a sustainable business model.
In an internal report viewed by CNBC about the potential of the biotech industry and gene therapy titled “The Genome Revolution,” analysts literally asked: “Is curing patients a sustainable business model?”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing,” wrote analyst Salveen Richter.
“However,” Richter continued, “such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.“
The report goes to show how since a hepatitis C drug that achieves a 90% cure rate has been available, the US sales for these treatment have fallen from 12.5 billion in 2015 to less than a projected 4 billion 3 years later.
An article written by Carey Wedler and published by Green Med Info comments further on this CNBC report, stating:
“Cancer is a highly profitable disease. In 2015, the world spent $107 billion on cancer drugs, and according to 2016 projections, that number was expected to grow to $150 by 2020. Further, Gilead Sciences, which Richter singled out as a company losing profits due to cures, was still the second most profitable pharmaceutical/biotech company in the world in 2017, earning over $12 billion in net income.”
The article then goes on to say Richter, who did not respond to CNBC’s request for comment, offered several ideas to cope with the ‘problem’ of healing patients. (my emphasis). He suggested targeting large markets, such as those suffering from hemophilia, because “Hemophilia is a nine to ten billion dollar market (hemophilia A, B), growing at ~6-7% annually.
The reason I am sharing this with you is to remind you that you need to be proactive in your care, whether for life-threatening, chronic or minor healthcare challenges. You need to look beyond the conventional allopathic pharmaceutical model (in which the majority of even the most caring and bright physicians have been marinated), to find the tools, the gifts of Mother Nature and the providers of such that can help you and your loved ones address these challenges. Often, these holistic interventions that more naturally address the physical and emotional aspects of healing can supplement and sometimes actually replace symptomatic treatment. They simply but powerfully aid your body in doing what it has been designed to do – to heal, regenerate and be whole.
Diet, essential oils, stress management, self-care, superfoods and wholefood supplements, spinal alignments, emotional work etc. are all such tools. And if you can find yourself a medical doctor who embraces them, all the better. The field of functional medicine provides such doctors but in the meanwhile, become a really good steward of your body, do your own research, and find providers such as a cancer coach, a nutritionist, essential oil experts, herbalists and others that willingly, and with knowledge, can support your healing journey.
It is my privilege to assist you on your healing journey.
*Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?” Tai Kim @firstadopter, Published 3:15 PM ET Wed, 11 April 2018 Updated 7:20 PM ET Wed, 11 April 2018. CNBC.com